Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Core Insights - Corbus Pharmaceuticals Holdings Inc. plans to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 on December 11, 2025, before market open [1] - A conference call and live webcast will be held on the same day at 8:00 am ET to discuss the Phase 1a data [1] About CRB-913 - CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (CB1), designed for weight loss with reduced brain penetration [3] - Preclinical models indicate that CRB-913 is 15-fold less brain-penetrant than monlunabant and has a 50 times lower brain:plasma ratio than rimonabant [3] About Corbus - Corbus Pharmaceuticals is focused on oncology and obesity, aiming to address serious illnesses through innovative scientific approaches [4] - The company's pipeline includes CRB-701, an antibody drug conjugate targeting Nectin-4 on cancer cells, and CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells [4]